PDF(Pubmed)
Abstract：
UNASSIGNED: This study evaluated the clinical results of zoledronic acid in the treatment of early osteonecrosis of the femoral head (ONFH).
UNASSIGNED: Study retrospectively analyzed 60 patients with zoledronic acid with bone marrow stem cell (BMSC) implantation (The study group) and 64 patients with BMSC implantation (The control group). The primary evaluation index included VAS, HHS, collapsed rate, and total hip replacement arthroplasty (THA) conversion rate.
UNASSIGNED: The study group had a lower VAS (1.12 ± 0.22 vs 1.44 ± 0.32) and higher HHS (75.07 ± 3.66 vs 68.78 ± 2.24) compared to the control group in 6 months after surgery (P < 0.05). In the study group, 12 hips (20%) collapsed, and 7 of 60 hips (11.67%) required THA surgery at the last follow-up. However, 25 hips (38.8%) collapsed in the control group, and 19 hips (29.69%) required THA surgery. The study group had a lower collapsed rate (P = 0.029) and THA conversion rate (P = 0.016) in survival analysis.
UNASSIGNED: Zoledronic acid and BMSC implantation in the treatment of early ONFH is safe and effective, reduces pain shortens recovery time, and reduces collapsed rate and THA conversion rate in ONFH patients.
UNASSIGNED: Study retrospectively analyzed 60 patients with zoledronic acid with bone marrow stem cell (BMSC) implantation (The study group) and 64 patients with BMSC implantation (The control group). The primary evaluation index included VAS, HHS, collapsed rate, and total hip replacement arthroplasty (THA) conversion rate.
UNASSIGNED: The study group had a lower VAS (1.12 ± 0.22 vs 1.44 ± 0.32) and higher HHS (75.07 ± 3.66 vs 68.78 ± 2.24) compared to the control group in 6 months after surgery (P < 0.05). In the study group, 12 hips (20%) collapsed, and 7 of 60 hips (11.67%) required THA surgery at the last follow-up. However, 25 hips (38.8%) collapsed in the control group, and 19 hips (29.69%) required THA surgery. The study group had a lower collapsed rate (P = 0.029) and THA conversion rate (P = 0.016) in survival analysis.
UNASSIGNED: Zoledronic acid and BMSC implantation in the treatment of early ONFH is safe and effective, reduces pain shortens recovery time, and reduces collapsed rate and THA conversion rate in ONFH patients.
摘要：
■本研究评估了唑来膦酸治疗早期股骨头坏死（ONFH）的临床效果。
■研究回顾性分析了60例唑来膦酸骨髓干细胞（BMSC）植入患者（研究组）和64例BMSC植入患者（对照组）。主要评价指标包括VAS、HHS,崩溃率，和全髋关节置换术(THA)转换率。
■术后6个月，研究组的VAS评分（1.12±0.22vs1.44±0.32）和HHS评分（75.07±3.66vs68.78±2.24）均低于对照组（P<0.05）。在研究小组中,12臀部（20%）塌陷，在最后一次随访时，60髋中的7髋（11.67％）需要THA手术。然而,对照组25髋(38.8%)塌陷,19髋（29.69％）需要THA手术。在生存分析中，研究组的塌陷率（P=0.029）和THA转换率（P=0.016）较低。
■唑来膦酸和BMSC植入治疗早期ONFH是安全有效的，减少疼痛缩短恢复时间，并降低ONFH患者的塌陷率和THA转化率。
■研究回顾性分析了60例唑来膦酸骨髓干细胞（BMSC）植入患者（研究组）和64例BMSC植入患者（对照组）。主要评价指标包括VAS、HHS,崩溃率，和全髋关节置换术(THA)转换率。
■术后6个月，研究组的VAS评分（1.12±0.22vs1.44±0.32）和HHS评分（75.07±3.66vs68.78±2.24）均低于对照组（P<0.05）。在研究小组中,12臀部（20%）塌陷，在最后一次随访时，60髋中的7髋（11.67％）需要THA手术。然而,对照组25髋(38.8%)塌陷,19髋（29.69％）需要THA手术。在生存分析中，研究组的塌陷率（P=0.029）和THA转换率（P=0.016）较低。
■唑来膦酸和BMSC植入治疗早期ONFH是安全有效的，减少疼痛缩短恢复时间，并降低ONFH患者的塌陷率和THA转化率。
